H.C. Wainwright analyst Yi Chen reiterated a Buy rating on HTG Molecular Diagnostics (HTGM – Research Report) today and set a price target of $15.00. The company’s shares closed last Friday at $3.33.
Chen covers the Healthcare sector, focusing on stocks such as Applied DNA Sciences, Vaccitech Plc, and Veru. According to TipRanks, Chen has an average return of -12.2% and a 30.88% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for HTG Molecular Diagnostics with a $8.00 average price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $55.31 and a one-year low of $2.38. Currently, HTG Molecular Diagnostics has an average volume of 1.12M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
HTG Molecular Diagnostics, Inc. engages in the provision of molecular technology solutions that facilitates molecular profiling. Its customers include biopharmaceutical companies, academic research centers, and molecular testing laboratories. The company was founded by Bruce E. Seligmann in October 1997 and is headquartered in Tucson, AZ.
Read More on HTGM:
- HTG Announces Certain Preliminary 2022 Unaudited Financial Results
- HTG Molecular reports preliminary 2022 revenue $6.4M, two est. $5.7M
- H.C. Wainwright institutes $15 price target on HTG Molecular shares
- HTG Molecular provides highlights of second event in KOL webcast series
- HTG Molecular Diagnostics Provides Highlights of its Second Event in Drug Discovery KOL Webcast Series
